

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the “Shanghai Junshi Biosciences Co., Ltd.* Announcement on the Result of the Reduction in Shareholding of the Shareholder” published by Shanghai Junshi Biosciences Co., Ltd.* on the website of the Shanghai Stock Exchange, for reference purpose only. The following is a translation of the official announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 10 August 2026

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Wang Gang and Dr. Li Xin as executive Directors; Dr. Yao Sheng and Mr. Tang Yi as a non-executive Director; and Dr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun, Dr. Yang Jin and Mr. Chen Liang as independent non-executive Directors.

* For identification purposes only

Shanghai Junshi Biosciences Co., Ltd.*
Announcement on the Result of the Reduction in
Shareholding of the Shareholder

The board of directors, all directors and relevant shareholders of the Company warrant that the contents of the announcement do not contain any false and misleading representation or material omission, and shall undertake legal liabilities in accordance with the law for the truthfulness, accuracy and completeness of the contents herein.

Important notice:

● Basic shareholding information of the substantial shareholder

Before the plan for the reduction in shareholding, Ms. He Ming held 3,531,380 shares in Shanghai Junshi Biosciences Co., Ltd. (the “Company”), all of which were A shares, accounting for 0.3440% of total share capital of the Company. Among the aforesaid shares, 3,530,580 shares were acquired through the division of assets in accordance with the law, following the dissolution of her marriage with Mr. Li Cong, an executive director and the co-CEO of the Company. and the restrictions on sale of the shares have been lifted and the shares have been listed for trading since 2 January 2024.

● Result of the plan for the reduction in shareholding

On 24 April 2026, the Company disclosed the “Announcement on the Plan for the Reduction in the Shareholding of the Shareholders” (Announcement No.: Lin 2026-025) on the website of Shanghai Stock Exchange (www.sse.com.cn). Due to the personal funding needs, Ms. He Ming planned to reduce the shareholding in the Company by no more than 882,600 shares in total through centralized bidding, and the total reduction ratio did not exceed 0.0860% of the total share capital of the

Company. The duration of reduction in shareholding was from 20 May 2026 to 19 August 2026.

The Company received the “Notice on the Result of the Reduction in Shareholding of Junshi Biosciences” (《關於君實生物減持股份結果的告知函》) issued by Ms. He Ming recently. The plan for reduction in shareholding of Ms. He Ming has been implemented.

I. Basic Information on the Subject of the Reduction in Shareholding Before the Reduction in Shareholding

Name of shareholder	He Ming
Capacity of shareholder	Controlling shareholder, actual controller and party acting in concert ☐ Yes ☒ No Shareholder directly holding more than 5% of shares ☐ Yes ☒ No Director, supervisor and senior management ☐ Yes ☒ No Others: Former spouse of director or senior management
Number of shares held	3,531,380 shares
Shareholding percentage	0.3440%
Source of shares currently held	Acquired through other means: 3,530,580 shares Acquired through centralized bidding: 800 shares

The aforesaid subject entity of the reduction in shareholding has no parties acting in concert.

II. Result of the Plan for the Reduction in Shareholding

(i) Shareholder disclose the result of the plan for the reduction due to the following matter:

Disclosed share reduction plan has been implemented.

Name of shareholder	He Ming
First disclosure date of the plan for the reduction in shareholding	24 April 2026
Number of shares reduced (share)	882,600 shares
Duration of reduction in shareholding	3 July 2026~10 August 2026
Methods for reduction in shareholding and corresponding number of shares reduced	For reduction in shareholding acquired by division of assets from Mr. Li Cong through centralized bidding: 882,600 shares
Price range of reduction in shareholding (RMB/share)	RMB 35.76~40.34 per share
Total amount of reduction in shareholding	RMB 33,543,382.60
Completion of reduction in shareholding	Completed
Percentage of reduction in shareholding	0.0860%
Percentage of proposed reduction in shareholding	Not more than: 0.0860%
Current shareholding	2,647,980 shares
Current shareholding percentage	0.2579%

- (ii) Whether the reduction in shareholding is in compliance with the relevant laws and regulations and the business rules of the stock exchange ☒Yes ☐No
- (iii) Whether the actual reduction in shareholding is consistent with the plan and undertakings previously disclosed ☒Yes ☐No
- (iv) Whether the reduction was not implemented after the expiration of the reduction period ☐Not implemented ☒Implemented
- (v) Whether the actual reduction failed to achieve the minimum reduction quantity (ratio) specified in the reduction plan ☐Not achieved ☒Achieved
- (vi) Whether to terminate the share reduction plan in advance ☐Yes ☒No
- (vii) Whether there is any violation of the plan or other undertakings ☐Yes ☒No

Announcement is hereby given.

Shanghai Junshi Biosciences Co., Ltd.*

Board of Directors

11 August 2026